clinical_trials
Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement
Confidence86·multiple reportsImportance88NP-EVT-20261109-174F350
(MedPage Today) -- In patients treated with resmetirom (Rezdiffra), early responses in blood and imaging biomarkers were associated with resolution of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis improvement, according to...
Read the original at the primary source
Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement
11/9/2026, 10:33:40 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —